
When pharmaceutical supplier Orifarm bought a wide range of products from Japanese Takeda for DKK 4.6bn (USD 726.0m) in March 2020, the company was – in the words of CEO Erik Sandberg – "in the eye of the hurricane". At that time, Covid-19 was on everybody's lips and there was a vast amount of uncertainty. The uncertainty, however, led to the purchase casting off a significant "pandemic discount", says Sandberg, according to Danish newspaper Børsen.
"We had an opportunity to negotiate our way down to a super attractive pricing level, so we got a solid Covid-19 discount. We did. The timing was in our favor," Sandberg tells the newspaper.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app